Date sent: 29 November 2007
On 20th November the Brussels Declaration signatories, including the IPCRG, launched a new report by the Centre for European Policy Studies (CEPS) Asthma in the EU: towards better management and regulation of a public health issue. http://www.theipcrg.org/news/index.php It helps identify what actions can be done at a Europe-wide level and what require national attention. It concludes that the most scope for improvement at European level is through 4 things:
- Influencing the European Medicines Agency (EMEA) process for assessment of medicinal products, such as asthma therapy, which “ lackstransparency and fails to involve relevant stakeholders such as patient and clinician representatives in a formalised way.
- Improving the monitoring of post-approval adverse reactions, known as pharmacovigilance, so that it captures real-life situations where much care is self-managed.
- Supporting member states to identify best practice through the Open Method of Coordination (OMC); this might enable best practice such as the Finnish model, to be shared across member states.
- Communicating best practice through methods such as disease-specific fact sheets.
Siân Williams, Executive Officer
29th November 2007